In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Divergent effects of C338A polymorphism of endothelin-1 converting enzyme gene, on endothelin-1 levels is healthy subjects and in subjects with coronary artery disease

Session Poster session 4

Speaker Evangelos Oikonomou

Event : ESC Congress 2014

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : Coronary Artery Disease (Chronic)
  • Session type : Poster Session

Authors : E Toli (Athens,GR), D Tousoulis (Athens,GR), C Antoniades (Athens,GR), A Miliou (Athens,GR), G Hatzis (Athens,GR), N Papageorgiou (Athens,GR), L Kormali (Athens,GR), E Oikonomou (Athens,GR), E Tsiamis (Athens,GR), C Stefanadis (Athens,GR)

Authors:
E. Toli1 , D. Tousoulis1 , C. Antoniades1 , A. Miliou1 , G. Hatzis1 , N. Papageorgiou1 , L. Kormali1 , E. Oikonomou1 , E. Tsiamis1 , C. Stefanadis1 , 1University of Athens Medical School, 1st Cardiology Department, “Hippokration” Hospital - Athens - Greece ,

Citation:
European Heart Journal ( 2014 ) 35 ( Abstract Supplement ), 652

Purpose: Endothelin-1 (ET-1) is strongly implicated into the pathophysiology of atherosclerosis and of ischemic heart disease. Although a number of genetic polymorphisms have been identified in ET-1 gene, their effects on the expression of ET-1 and its circulating levels are unclear. We examined the effect of C338A polymorphism of endothelin-1 converting enzyme gene (ECE-1b C338A) on ET-1 levels in coronary artery disease (CAD) patients and control subjects.

Methods: The study population consisted of 151 (mean age 61±10 years) consecutive subjects with angiographically documented stable CAD and 190 (mean age 60±10 years) control subjects. Plasma levels of ET-1 were measured by ELISA, while the presence of (ECE-1b C338A) polymorphism was determined by PCR.

Results: Between CAD and control subjects there was no difference in age while the prevalence of male gender was higher among CAD subjects (78% vs. 58%, p<0.001). Subjects with CAD had also significantly elevated levels of ET-1 compared to control subjects (2.38±2.94fmol/ml vs. 1.24±1.25fmol/ml, p<0.001) even after adjustment for gender. However, there was no significant difference in the distribution of ECE-1b C338A polymorphism between CAD (CC: 88%, CA: 8%, AA: 5%) and control subjects (CC: 87%, CA: 7%, AA: 6%), (p=0.84). Interestingly, in CAD subjects the presence of A allele on ECE-1b C338A polymorphism was associated with significantly increased levels of ET-1 (5.43±1.96fmol/ml vs. 1.96±2.33fmol/ml, p<0.001) while in control subjects the presence of A allele on ECE-1b C338A polymorphism had no impact on ET-1 levels (1.40±1.13fmol/ml vs. 1.22±1.26fmol/ml, p=0.41).

Conclusions: The presence of A allele on ECE-1b C338A polymorphism is associated with significantly higher levels of ET-1 in CAD patients. These findings may partially explain the difference observed in ET-1 levels between control subjects and CAD patients and provide further insights into the pathophysiology of atherosclerosis and of ischemic heart disease.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are